
Alebund
专注于肾脏疾病及相关慢性病领域的生物医药公司礼邦医药(Alebund Pharmaceuticals,香港联合交易所股份代号:09637,以下简称“公司”)今日发布截至 2026 年 6 月 30 日止六个月(“报告期”)的未经审核中期业绩。报告期内及直至中期业绩公告日期,公司在临床开发、外部合作、于中国的商业化及资本市场等四方面同时取得重要进展。
Series B+ ·
Amount not disclosed in a source on record.
Funding history ↓Signals
Website registeredMay 18, 2018 (8 years old)
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series B+ | undisclosed | — | fundraisingfox.com |
Timeline
- Website created
Similar Health and bio companies
VVumedi$140M Series B+ · Nov 2026
NNeurosterix$105M Series B+ · Nov 2026
OOSMUNDA$14.99M Series B+ · Nov 2026
BBoston Medical Sciences$34.69M Series B+ · Nov 2026
AAraceli Biosciences$4.5M Seed · Nov 2026
PPhrontline Biopharma$40M Series A · Nov 2026
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/alebund (get a free API key).